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OBJECTIVES: To determine the safety and efficacy of human chorionic 
gonadotropin hormone-derivative EA-230 in cardiac surgery patients. 
Cardiac surgery induces systemic inflammation and may impair renal func-
tion, affecting patient outcome. EA-230 exerted immunomodulatory and 
renoprotective effects in preclinical models and was safe and showed effi-
cacy in phase I and II human studies.
DESIGN: Double-blinded, placebo-controlled, randomized study.
SETTING: Collaboration of the Cardiothoracic Surgery, Anesthesiology, 
and the Intensive Care departments of a tertiary hospital in the Netherlands.
PATIENTS: One hundred eighty patients undergoing an on-pump coro-
nary artery bypass procedure with or without concomitant valve surgery.
INTERVENTIONS: Ninety mg/kg/hr EA-230 or placebo administered 
during surgery.
MEASUREMENTS AND MAIN RESULTS: During the study, no safety 
concerns emerged. EA-230 did not modulate interleukin-6 plasma concen-
trations (area under the curve 2,730 pg/mL × hr [1,968–3,760] vs 2,680 
pg/mL × hr [2,090–3,570] for EA-230 and placebo group, respectively; 
p = 0.80). Glomerular filtration rate increased following surgery (mean ± 
sem increase in the EA-230 vs placebo groups: glomerular filtration rateiohexol 
measured using iohexol plasma clearance: 19 ± 2 vs 16 ± 2 mL/min/1.73 m2; 
p = 0.13 and estimated glomerular filtration rate with the Modification of Diet 
in Renal Disease equation using creatinine: 6 ± 1 vs 2 ± 1 mL/min/1.73 m2; 
p = 0.01). The “injury” stage of the Risk, Injury, Failure, Loss of kidney func-
tion, and End-stage kidney disease criteria for acute kidney injury was 7% 
in the EA-230 group versus 18% in the placebo group (p = 0.07). In addi-
tion, EA-230-treated patients had a less positive fluid balance compared with 
placebo-treated patients (217 ± 108 vs 605 ± 103 mL; p = 0.01), while the 
use of vasoactive agents was similar in both groups (p = 0.39). Finally, hos-
pital length of stay was shorter in EA-230 treated patients (8 d [7–11] vs 10 
d [8–12]; p = 0.001). Efficacy results were more pronounced in patients that 
had longer duration of surgery and thus longer duration of study drug infusion.
CONCLUSIONS: EA-230 was safe in patients undergoing on-pump car-
diac surgery. It did not modulate interleukin-6 plasma concentrations but 
appeared to exert beneficial renal and cardiovascular effects and short-
ened in-hospital length of stay.
KEY WORDS: acute kidney injury; cardiac surgery; EA-230; 
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Systemic activation of the immune system, as a re-sult of pronounced (surgery-induced) tissue in-jury or infection, affects most critically ill patients 
admitted to the ICU (1–4). It is well recognized that 
a dysregulated systemic inflammatory response is as-
sociated with organ dysfunction (5, 6), as exemplified 
by the relationship between cytokine levels and the 
occurrence and severity of acute kidney injury (AKI) 
(7–9). To date, no pharmacologic interventions are li-
censed to limit systemic inflammation or protect renal 
function (10–13).
Open-heart surgery is performed in over 2 mil-
lion patients annually worldwide (14). This procedure 
induces a systemic inflammatory response (3) and is 
associated with an approximate 20% risk of developing 
AKI (11, 15, 16). Activation of blood components by 
the use of cardiopulmonary bypass (CPB), surgically 
induced tissue damage, ischemia-reperfusion injury 
following aortic cross-clamping and endotoxemia due 
to translocation of gut bacteria play a role in the ac-
tivation of the immune system, resulting in increased 
capillary permeability, loss of vascular tone, and organ 
tissue injury (3, 17–19).
Immunotolerance during pregnancy allows for 
the improbable symbiosis of two major histocom-
patibility complex-incompatible individuals (20, 21). 
Remarkably, several autoimmune diseases improve in 
pregnant women without increasing susceptibility to 
develop infections (22–25). In addition, the glomer-
ular filtration rate (GFR) increases (26). This favor-
able immune-tolerant phenotype and increase in GFR 
observed during pregnancy has been attributed to the 
human chorionic gonadotropin (hCG) hormone and 
has led to the discovery of EA-230, a hCG-derived 
linear tetrapeptide. Treatment with EA-230 attenuated 
pro-inflammatory cytokine release, prevented organ 
dysfunction and renal injury, and improved survival in 
several animal models of systemic inflammation (27–33). 
Furthermore, EA-230 mitigated renal injury and 
improved survival in murine models of renal transplan-
tation and renal ischemia-reperfusion injury (34–36). 
Finally, EA-230 was shown to be well tolerated in phase 
1 studies (37) and attenuated the release of inflamma-
tory mediators during experimental human endotox-
emia (38).
The purpose of the current phase 2 clinical study was to 
determine the safety and immunomodulatory and reno-
protective effects of EA-230 in cardiac surgery patients.
MATERIALS AND METHODS
Study Design and Participants
This first inpatient randomized, double-blind, pla-
cebo-controlled phase 2 study was conducted in 
patients undergoing elective on-pump cardiac surgery. 
The study was approved by the local ethics commit-
tee and conducted in accordance with the Declaration 
of Helsinki and in compliance with the International 
Conference on Harmonisation E6 Guideline for Good 
Clinical Practice (CPMP/ICH/135/95), the Dutch 
Medical Research Involving Human Subjects Act, and 
the European Directive (2001/20/CE). The study pro-
tocol, including a detailed statistical analysis plan, was 
published previously (39) (full protocol in Methods 
S5, http://links.lww.com/CCM/G113).
For safety reasons, the study was conducted in two 
phases. After inclusion of 60 (low-risk) patients in the 
first phase (criteria listed in Methods S1, http://links.
lww.com/CCM/G113), enrollment was interrupted for 
an independent interim safety analysis by the Data Safety 
Management Board (DSMB). Enrollment of both low- 
and high-risk patients was continued in the second phase 
of the study. Following inclusion of 90 patients, the DSMB 
conducted a second safety analysis and an early efficacy 
analysis and recalculated the sample size with intrinsic 
study data according to the adaptive trial design (sum-
mary in Methods S2, http://links.lww.com/CCM/G113).
Patients older than 18 years scheduled for elective cor-
onary artery bypass grafting (CABG) procedure, with or 
without valve surgery, with use of CPB were eligible for 
participation. A standardized protocol was used for the 
surgical procedure and anesthetic management. Patients 
that were immune-compromised were excluded (proce-
dural protocol details and full in- and exclusion criteria 
in Methods S1, http://links.lww.com/CCM/G113).
Randomization and Intervention
Patients were randomized in a 1:1 ratio to receive ei-
ther EA-230 (90 mg/kg/hr throughout the surgical 
procedure) or placebo (sodium chloride with identical 
osmolality, appearance, and texture as the EA-230 so-
lution), both manufactured by HALIX BV (Leiden, The 
Netherlands) and provided by the study sponsor. Study 
drug was administered from surgical incision until the 
end of CPB with a maximum of 4 hours of infusion 
aimed to cover the period during which the inflamma-
tory insults originated. This dosage exerted significant 
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immunomodulatory effects during experimental 
human endotoxemia (38). A stratified randomization 
procedure was conducted using the GCP-approved data 
management software Castor EDC (Amsterdam, The 
Netherlands) to equally distribute patients according to: 
1) a CABG procedure with or without valve surgery; 2) 
preoperative renal function with an estimated GFR of 
less than or equal to 30, 31–90, or greater than 90 mL/
min/1.73 m2; and 3) a EuroSCORE II of less than 4 or 
greater than or equal to 4 (40). Apart from the inter-
vention, all patients received clinical care as usual. All 
attending physicians, study personnel, and patients 
were blinded to treatment allocation (detailed study 
and blinding procedures are described in Methods S5, 
http://links.lww.com/CCM/G113).
Safety
The primary endpoint was safety and tolerability of 
EA-230, assessed by monitoring of: 1) vital signs: heart 
rate and blood pressure during postoperative ICU ad-
mission, 2) routine laboratory variables until the first 
postoperative day, and 3) frequency of (serious) ad-
verse events ([S]AEs) and suspected unexpected se-
rious adverse reactions until day 90 post-surgery. Only 
treatment-emergent SAEs are presented. Furthermore, 
major clinical adverse events (MCAEs) related to car-
diac surgery were registered: cerebrovascular acci-
dents, myocardial infarction, rethoracotomy, hospital 
readmission, and pleural and/or pericardial puncture.
Efficacy—Inflammation
Immunomodulatory effects of EA-230 were quantified 
by comparing the area under the plasma concentra-
tion-time effect curves (AUECs) of interleukin (IL)-6 
from pre-surgery until the first postoperative day. In 
addition, other inflammatory mediators (IL-8, IL-10, 
IL-17, tumor necrosis factor-α, monocyte chemo-
attractant protein-1, IL-1 receptor antagonist, mac-
rophage inflammatory protein [MIP]-1α, MIP-1β, 
intercellular adhesion molecule-1, and vascular cell 
adhesion protein-1), leukocyte counts, body tempera-
ture, and insulin sensitivity were determined (detailed 
in Methods S3, http://links.lww.com/CCM/G113).
Efficacy—Renal
Effects of EA-230 on renal function were assessed 
by determining the GFR using plasma clearance of 
iohexol (GFRiohexol) (41), plasma concentrations of cre-
atinine and the Modification of Diet in Renal Disease 
(MDRD) equation to estimate GFR (eGFRGFRMDRD), 
and creatinine clearance to calculate the endogenous 
creatinine clearance  (GFRECC) (42). Furthermore, the 
occurrence rate of different stages of AKI was regis-
tered during hospital admission according to the Risk, 
Injury, Failure, Loss of kidney function, and End-stage 
kidney disease (RIFLE) criteria (43). Finally, urinary 
excretion of creatinine, urea, and tubular injury mark-
ers was determined serially (detailed in Methods S3, 
http://links.lww.com/CCM/G113).
Efficacy—Cardiovascular
Cardiopulmonary variables (vasoactive or inotropic 
agent requirement, expressed as the “inotropic score” 
during ICU admission [44], fluid balance, and the 
pulmonary alveolar-arterial [A-a] gradient) were 
determined.
Efficacy—General Clinical Effects
General patient outcome measures were disease se-
verity with the Acute Physiology and Chronic Health 
Evaluation (APACHE) IV and Sequential Organ 
Failure Assessment (SOFA) score, the ICU and hos-
pital length of stay, and 90-day mortality.
Sample Size Calculation and Statistical Analysis
Efficacy outcome variable IL-6 was used for the sample 
size calculations using data of a previous study (38) 
(detailed in Methods S4, http://links.lww.com/CCM/
G113). Early efficacy analysis and a final sample size 
recalculation were performed halfway the study by 
the DSMB, according to the adaptive study design 
(detailed in Methods S2, http://links.lww.com/CCM/
G113). The study team was blinded to these interim 
analyses.
Continuous variables are presented as mean with 
sem, or median with interquartile range (IQR), depend-
ing on their distribution (determined by Shapiro-Wilk 
tests). Geometric mean and 95% CI are used for the 
inotropic score. Measurements over time were analyzed 
using repeated measures two-way analysis of variance 
(on log-transformed data in case of non-normally dis-
tributed data). Other data were tested using Student 
t tests or Mann-Whitney U tests, for parametric and 
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nonparametric data, respectively. Categorical data are 
presented as frequencies and percentages and were 
analyzed using Pearson chi-squared tests or Fisher 
exact tests. Time to event data were analyzed using 
log-rank tests.
The intention-to-treat population consisted of all 
patients who received study medication and their safety 
analyses were reported. The per-protocol population 
consisted of all patients without any major protocol 
deviation during the study and their efficacy analyses 
were reported. The subgroups created by stratified ran-
domization were analyzed separately.
Post hoc analyses on immunomodulating, reno-
protective, and cardiovascular effects of EA-230 were 
performed in patients with below and above median 
durations of surgery, as duration of surgery induces 
a more pronounced inflammatory response and also 
implies longer duration of study drug administration.
Statistical analyses were conducted using SAS 
Version 9.3 (SAS, Cary, NC) and SPSS Version 25 
(IBM, Armonk, NY).
RESULTS
One-hundred eighty patients were enrolled between 
July 2016 and November 2017. Ninety-one patients 
were randomized to receive EA-230 and 89 to receive 
placebo treatment (Fig. 1). In one patient, the sur-
geon decided to perform an off-pump procedure after 
sternotomy was performed. This patient was therefore 
considered a secondary exclusion and followed-up for 
safety analysis only. Stratified randomization equally 
distributed patients between treatment groups (Table 1 
and Fig. 1), results of these strata subgroups are sum-
marized in Table S1 (http://links.lww.com/CCM/
G114). No major protocol deviations occurred and 
double-blind conditions were maintained at all times. 
Baseline characteristics are listed in Table 1.
Safety
A total of 500 AEs were reported. In the EA-230 group, 
217 AEs and 13 SAEs occurred, compared with 283 
AEs and 19 SAEs in the placebo group. There were no 
(S)AEs judged “probably” or “definitely” related to the 
study drug. Eleven patients treated with EA-230 (11%) 
experienced a MCAE compared with 15 patients (17%) 
of the placebo group. Routine laboratory variables and 
vital signs were similar between treatment groups. 
Safety results are listed in Table 2 (primary) and Table S2 
(http://links.lww.com/CCM/G114) (detailed).
Efficacy—Inflammation
AUEC plasma IL-6 concentrations were not differ-
ent between the EA-230 and placebo groups (me-
dian [IQR] AUEC of 2,730 pg/mL × hr [1,968–3,760] 
and 2,680 pg/mL.× hr [2,090–3,570] in the EA-230 
and placebo groups, respectively; p = 0.80; Fig. 2A). 
Differences between treatment groups within sub-
groups were not significant (EA-230 vs placebo in 
short [p = 0.88] and long duration of surgery [p = 
0.41]; Fig. 3). No effect of EA-230 on other circulating 
inflammatory mediators was observed (Figs. S1 and 
S2, http://links.lww.com/CCM/G114). Furthermore, 
no difference between treatment groups in leukocyte 
count, body temperature, A-a gradient, insulin dose, 
and glucose concentrations was observed (Table 2; and 
Fig. S3, http://links.lww.com/CCM/G114).
Efficacy—Renal
In both groups, the GFRiohexol was higher on the 
first postoperative day compared with the day be-
fore surgery; this increase was not different between 
treatment groups (mean ± sem delta of 19 ± 2 mL/
min/1.73 m2 and 16 ± 2 mL/min/1.73 m2 in the 
EA-230 and placebo group, respectively; p = 0.13; 
Fig. 2B). Nevertheless, higher urinary creatinine 
and urinary urea concentrations were observed in 
the EA-230 group compared with the placebo group 
(p = 0.03 and 0.004, respectively) (Table  2; and 
Fig. S4, http://links.lww.com/CCM/G114), corre-
sponding with a decrease in plasma creatinine con-
centrations observed in the EA-230 group, but not 
in the placebo group (mean ± sem delta of –6 ± 1 
µmol/L vs +1 ± 2 µmol/L in the EA-230 and placebo 
group, respectively; p = 0.003) (Fig. S4, http://links.
lww.com/CCM/G114). This difference remained sta-
tistically significant over the first 7 postoperative days 
(p = 0.02) (Fig. S4, http://links.lww.com/CCM/G114). 
In accordance with the latter results, a significant dif-
ference between treatment groups in eGFRMDRD was 
found from baseline until the first postoperative day 
(mean ± sem delta of 6 ± 1 vs 2 ± 1 mL/min/1.73 
m2 in the EA-230 and placebo group, respectively; 
p = 0.01; Fig. 2B). For patients with a longer duration 
of surgery, treatment with EA-230 augmented both 
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the increase in GFRiohexol (p = 0.02) and eGFRMDRD 
(p = 0.0002) compared with placebo, whereas no differ-
ence between treatment groups for patients with a short 
duration of surgery was observed (GFRiohexol p = 0.47 
and eGFRMDRD p = 0.27) (Fig.  3). Urine output was 
similar between treatment groups (p = 0.30) (Table 2 
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perform surgery without CPB
Randomizaon strata
73 with valve surgery
16 no valve surgery
2 eGFR ≤ 30
63 eGFR 31-90
24 eGFR > 90
5 euroSCORE II ≥ 4
84 euroSCORE II < 4
Randomizaon strata
78 with valve surgery
12 no valve surgery
2 eGFR ≤ 30
64 eGFR 31-90
24 eGFR > 90
4 euroSCORE II ≥ 4
86 euroSCORE II < 4
Figure 1. Study flowchart. CPB = cardiopulmonary bypass, eGFR = estimated glomerular filtration rate.
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TABLE 1. 





(n = 89) p
Age (yr) 67 ± 0.9 68 ± 1.0 0.40
Gender, n (%) 0.63
 Male 80 (51) 77 (49)  
 Female 10 (46) 12 (54)
Weight (kg) 86 ± 2 87 ± 2 0.89
Height (cm) 175 ± 1 176 ± 1 0.61
Body mass index (mass/height2) 28 ± 0.4 28 ± 0.4 0.87
EuroSCORE II 1.6 ± 0.1 1.8 ± 0.1 0.39
Study drug treatment duration (min) 156 ± 4 153 ± 4 0.65
 Below median duration (min) 126 ± 2 124 ± 2 0.46
 Above median duration (min) 183 ± 4 187 ± 5 0.59
Cardiopulmonary bypass duration (min) 95 ± 3.8 95 ± 4.4 0.99
Aortic clamping duration (min) 57 ± 2.6 57 ± 3.2 0.97
Kidney function
 GFR using plasma clearance of iohexol (mL/min/1.73 m2) 79 ± 1.9 78 ± 1.9 0.67
 GFR with the Modification of Diet in Renal Disease (mL/min/1.73 m2) 79 ± 2.3 78 ± 18 0.62
 Plasma creatinine (µmol/L) 88 ± 2.9 87 ± 2.2 0.72
Subgroup stratification
 Valve surgery, n (%) 0.39
  Yes 78 (52) 73 (48)  
  No 12 (43) 16 (57)
 Estimated GFR pre-surgery, mL/min/1.73 m2, n (%) 1.00
  ≤ 30 2 (50) 2 (50)  
  31–90 64 (50) 63 (50)
  > 90 24 (50) 24 (50)
 EuroSCORE II, n (%) 0.72
  ≥ 4 4 (44) 5 (56)  
  < 4 86 (51) 84 (49)
GFR = glomerular filtration rate.
Data are presented as mean ± sd or count (%).
p values calculated using Student t tests or Pearson chi-squared   tests.
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TABLE 2. 
Safety and Efficacy Endpoints
Intention-to-Treat Population EA-230 (n = 91) Placebo (n = 89) p
Safety
 TE adverse events, number of events (n [%]) 217 (n = 78 [86]) 218 (n = 81 [91]) —
 TE serious adverse events, number of events (n [%]) 13 (n = 12 [13]) 19 (n = 17 [19]) —
 Suspected unexpected serious adverse reactions,  
 number of events (n [%])
0 (n = 0 [0]) 1 (n = 1 [1]) —
 Major clinical adverse event related to cardiac  
 surgery, number of events (n [%])
11 (n = 11 [12]) 15 (n = 15 [17]) —
Per-Protocol Population EA-230 (n = 90) Placebo (n = 89)  
Efficacy—inflammatory
 Interleukin-6 (peak in pg/mL) 189 [141–293] 213 [154–287] 0.99a
 Leukocyte numbers (peak in ×109/L) 13 [11–16] 13 [10–16] 0.25a
 Body temperature (peak in °C) 37.1 ± 0.06 37.4 ± 0.06 0.08a
 Insulin dose (total units during the first 24 hr  
 of ICU admission)
3.3 [0–25] 0 [0–26] 0.77a
 Glucose (peak in mmol/L) 9.0 ± 0.16 9.1 ± 0.16 0.58a
Efficacy—renal
 GFR using plasma clearance of iohexol (change from  
 day before surgery to POM in mL/min/1.73 m2)
19 ± 1.2 16 ± 2 0.13a
 GFRMDRD (change from day before surgery to POM in  
 mL/min/1.73 m2)
6 ± 1 2 ± 1 0.01a
 Occurrence rate of acute kidney injury, Risk, Injury, Failure,  
  Loss of kidney function, and End-stage kidney disease 
criteria stage “injury”
6 (7) 16 (18) 0.07b
 Plasma creatinine (change from day before surgery  
to POM in µmol/L)
–5.6 ± 1.1 1.1 ± 1.9 0.003a
 Plasma creatinine (peak during POD 1–7 in µmol/L) 82 ± 5 96 ± 11 0.02a
 GFRMDRD (lowest during POD 1–7 in mL/min/1.73 m
2) 86 ± 5 80 ± 5 0.66a
 GFR to calculate endogenous creatinine clearance (change 
 from day before surgery to POM in mL/min/1.73 m2)
106 ± 4 104 ± 5 0.70a





 Urinary creatinine (nadir in mmol/L) 4.1 [3.2–5.7] 3.7 [2.6–5.5] 0.03a
 Urinary urea (peak in mmol/L) 150 [112–189] 111 [81–144] 0.004a
(Continued)
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and Fig. S5, http://links.lww.com/CCM/G114). 
Considering AKI, the RIFLE stage “no AKI” was pre-
sent in 50 patients (56%) of the EA-230 group and 42 
patients (47%) of the placebo group, while stage “in-
jury” was observed in six patients (7%) of the EA-230 
group and 16 patients (18%) of the placebo group 
(p = 0.07; Fig. 2B). No significant differences in 
urinary excretion of tubular injury markers were 
observed between the two groups (Fig. S6, http://
links.lww.com/CCM/G114).
Efficacy—Cardiovascular
The net fluid balance was significantly lower in the 
EA-230 group compared with the placebo group on 
the first postoperative day (mean ± sem of 217 ± 108 
vs 605 ± 103 mL, respectively; p = 0.01) (Fig. 2C and 
Fig. S5, http://links.lww.com/CCM/G114), whereas 
vasopressor and/or inotropic therapy requirement 
(inotropic score) was not statistically different be-
tween groups (Fig. S5,  http://links.lww.com/CCM/
G114). In patients with a longer duration of surgery, 
treatment with EA-230 resulted in a significantly 
lower net fluid balance on the first postoperative day 
(p = 0.008) and a significantly lower inotropic score  
(p = 0.048) compared with placebo (Fig. 3). These 
effects were not observed in patients with a shorter 
duration of surgery (net fluid balance: p = 0.29 and 
inotropic score: p = 0.46; Fig. 3).
Efficacy—cardiovascular
 Net fluid balance (total mL during the first 24 hr  
of ICU admission)
787 ± 109 1,080 ± 117 0.98a
 Fluid therapy (total mL during the first 24 hr  






 Drain production (total mL during the first 24 hr  
 of ICU admission)
704 [558–913] 765 [578–932] 0.79a
 Alveolar-arterial gradient (change from ICU  
 admission to POM)
–9.7 ± 1.2 –8.6 ± 1.4 0.78a
Efficacy—general
 Length of stay in ICU (in hr) 21 [19–23] 22 [19–24] 0.02c
 Length of stay in hospital (in hr) 195 [171–265] 234 [192–295] 0.001c
 Sequential Organ Failure Assessment (change in score  
 from ICU admission to POM)
–1 [–2 to 1] –1 [–2.5 to 0] 0.35a
 Acute Physiology and Chronic Health Evaluation IV  
 (score at ICU admission)
53 ± 2 56 ± 2 0.26d
GFR = glomerular filtration rate, GFRMDRD = glomerular filtration rate with the Modification of Diet in Renal Disease, POD = postopera-
tive day, POM = postoperative morning, TE = treatment-emergent.
a p values calculated using repeated measures two-way analysis of variance (interaction term) on plasma concentration-time effect 
curves (depicted in supplemental material, http://links.lww.com/CCM/G114).
b  p values calculated using Pearson chi-squared  test.
c p values calculated using log-rank test.
d p values calculated using Mann-Whitney U tests or Student t tests, depending on the distribution of the data.
No statistical testing was performed on safety data. In Table S2 (http://links.lww.com/CCM/G114), safety data categorized on severity 
and organ class is reported.
Data are presented as mean ± sem or median [interquartile range] or frequency (percentage).
TABLE 2. (Continued).
Safety and Efficacy Endpoints
Intention-to-Treat Population EA-230 (n = 91) Placebo (n = 89) p
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Efficacy—General Clinical Effects
Both the ICU (p = 0.02) and hospital (p = 0.001) length of stay was 
shorter in patients treated with EA-230 compared with the placebo 
group (Fig. 2D). After 24 hours, 12% of patients treated with EA-230 
were still in the ICU compared with 23% of placebo-treated patients. 
The median [IQR] hospital length of stay was 8 days [7–11] and 10 
days [8–12] in the EA-230 and placebo group, respectively. EA-230 
exerted no significant effect on APACHE IV score at ICU admission 
(p = 0.29) and on SOFA scores from ICU admission to the first postop-
erative day (p = 0.49) (Table 2 and Fig. S7, http://links.lww.com/CCM/
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EA-230   90 17 3 1 1 1 0 90 31 4 4 2 0 0
Placebo   89 36 8 7 6 5 1 89 41 17 10 6 3 1
Figure 2. Efficacy endpoints. A, Inflammatory. 
Left: Plasma concentrations of interleukin 
(IL)-6 over time from preoperative time point 
(baseline) until the next postoperative morning 
(POM) (p = 0.99). Blue box indicates the 
period in which study drug was administered. 
Right: Area under the plasma concentration-
time effect curve of IL-6. Data presented 
as median and interquartile range. p values 
calculated using repeated measures two-way 
analysis of variance (interaction term, left) or 
Mann-Whitney U test (right). B, Renal.  
Left: Renal function expressed as glomerular 
filtration rate using plasma clearance of 
iohexol (GFRiohexol) and estimated glomerular 
filtration rate using the Modification of Diet 
in Renal Disease equation (eGFRMDRD) from 
the day before surgery (baseline) until the 
next POM. Data presented as mean and sem. 
p values calculated using repeated measures 
two-ay analysis of variance (interaction term). 
Right: Classification of acute kidney injury 
according to the Risk, Injury, Failure, Loss of 
kidney function, and End-stage kidney disease 
(RIFLE) criteria; patients were classified 
as “no acute kidney injury” (n = 50 in the 
EA-230 group, n = 42 in the placebo group), 
“Risk” (n = 34 in the EA-230 group, n = 31 
in the placebo group), or “Injury” (n = 6 in 
the EA-230 group, n = 16 in the placebo 
group), no patients were classified as stage 
“Failure,” “Loss of function,” or “End-stage of 
renal disease.” Data presented as percentages 
of patients. p value calculated using Pearson 
chi-squared test. C, Cardiovascular. Left: 
Net fluid balance during the first 24 hr 
after ICU admission (p = 0.97). Right: 
Cumulative postoperative net fluid balance 
on postoperative day (POD) 1 (n = 90 in the 
EA-230 group and n = 89 in the placebo 
group), on POD 2 (n = 90 in the EA-230 
group and n = 89 in the placebo group), and 
on POD 3 (n = 86 in the EA-230 group and n 
= 85 in the placebo). POD 4–7 not depicted 
due to few available data. Data presented 
as mean and sem. p values calculated using 
repeated measures two-way analysis of 
variance (interaction term, left) or Student t 
tests (right). D, General. Left: Length of stay 
in the ICU (p = 0.02). Right: Length of stay in 
the hospital (p = 0.001). p values calculated 
using log-rank test. CPB = cardiopulmonary 
bypass, HR = hazard ratio (the event is 
discharge).
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DISCUSSION
In patients following cardiac surgery with CPB, treat-
ment with EA-230 was well tolerated and no safety 
issues emerged. These results are similar to those 
obtained in healthy volunteers in the absence (37) and 
presence (38) of systemic inflammation. Treatment 
with EA-230 did not influence the immune response, 
but beneficial effects on renal and cardiovascular vari-
ables, and the ICU and hospital length of stay were 
observed.
The absence of immunomodulatory effects of 
EA-230 in the present work is in contrast to results 
obtained in several animal studies (28–31, 33) and a 
previous experimental human endotoxemia study 
(38). In the latter study, treatment with EA-230 atten-
uated the endotoxin-induced increase of IL-6 and sev-
eral other pro-inflammatory cytokines and resulted 
in significantly less pronounced fever and flu-like 
symptoms. Several differences between endotoxin- 
and cardiac surgery-induced inflammation can be put 
forward to explain this discrepancy. First, endotoxin 
administration results in activation of a single Toll-
like receptor 4-mediated inflammatory pathway only, 
whereas several other inflammatory pathways are acti-
vated in cardiac surgery patients. In the latter, surgical 
damage and stress result in the release of a multitude of 
danger-associated molecular patterns, ischemia-reper-
fusion injury, hemorrhagic shock, and possibly trans-
location of (components of) microorganisms from 
the gut to the circulation (3, 17–19). Nevertheless, 
previous animal studies have demonstrated immu-
nomodulatory effects of EA-230 in various types of 
inflammation, including models of ischemia-reper-
fusion injury (34–36), and hemorrhagic shock (31). 
These models recapitulate distinct aspects of the in-
flammatory response observed following cardiac sur-
gery and therefore may render this explanation for the 
absence of immunomodulatory effects in the current 
study less plausible. Second, the endotoxin-induced 
inflammatory response is short-lived, illustrated by 
a sharp but swift increase in plasma IL-6 concentra-
tions peaking at 2 hours following endotoxin admin-
istration (38), whereas cardiac surgery elicits a much 
more protracted and more limited inflammatory re-
sponse (IL-6 peaks approximately 6 hr after the start 
of surgery). Typically, timing of EA-230 administra-
tion in the endotoxin study overlapped with the peak 
endotoxin-induced IL-6 response, where in the present 
study, the peak IL-6 response emerged only at around 
6 hours. As dosing of EA-230 was limited to the du-
ration of cardiac surgery (aimed to cover the period 
the inflammatory insult originated), peak IL-6 levels 
did not overlap with EA-230 administration. Also, as 
the peak concentration was lower compared with that 
observed in the endotoxemia study, the inflammatory 
response following open-heart surgery may not be 
pronounced enough to detect an immunomodulating 
effect of EA-230 administered early during surgery.
Renal function measured using the clearance of 
iohexol was augmented on the first postoperative day 
in both groups, an increase in GFR that was not influ-
enced by treatment with EA-230. In contrast, EA-230 
treatment increased urinary excretion of creatinine 
and lowered plasma creatinine levels, resulting in 
improvements of creatinine-based GFR estimations. It 
is important to realize that the GFR determined by the 
clearance of iohexol over 4 hours reflects the GFR dur-
ing that specific period, while plasma creatinine-based 
estimations reflect the GFR during the 12–24 hours 
before plasma creatinine measurement. Therefore, the 
timing of the iohexol-based GFR measurement is cru-
cial and could have either been too early or too late to 
detect a possible effect of EA-230 on renal function. 
Furthermore, analysis based on AKI staging suggests 
that patients treated with EA-230 may be less likely 
to develop AKI. Based on these data, treatment with 
EA-230 appears to exert beneficial effects on early 
changes in renal function following cardiac surgery. 
Of interest, in patients with more prolonged surgery, 
a more pronounced effect of EA-230 on renal function 
was observed (in both GFRiohexol and eGFRMDRD), sug-
gesting that the duration of EA-230 infusion is of im-
portance for its therapeutic efficacy.
Treatment with EA-230 resulted in a significant re-
duction of the positive postoperative fluid balance, 
importantly without the need for higher doses of, or 
longer treatment with vasopressor or inotropic agents. 
Again, in patients with more prolonged surgery, these 
effects of EA-230 were more pronounced; differences 
in net fluid balance were more pronounced and less 
need for vasopressor therapy reached statistical signif-
icance compared with the control group. Increasing 
evidence suggests that reduction of the positive post-
operative fluid balance improves patient outcome in 
both critically ill and surgical ICU patients (45, 46).
van Groenendael et al
























































































Figure 3. Post hoc analyses using the subgroups short (n = 90) and long (n = 89) surgery duration (divided using median). A, Area 
under the plasma concentration-time effect curve (AUEC) of interleukin (IL)-6 plasma concentrations tested between treatment groups 
(short: EA-230 vs placebo: p = 0.88 and long: EA-230 vs placebo: p = 0.41). Data presented as median and interquartile range (IQR). 
B, Net fluid balance per day (short: p = 0.54, p = 0.33, p = 0.75, and p = 0.84 for first ICU day, postoperative day [POD] 1, POD 2, 
and POD 3, respectively. Long: p = 0.09, p = 0.008, p = 0.09, and p = 0.89 for first ICU day, POD 1, POD 2, and POD 3, respectively). 
Data presented as mean and sem. C, Vasoactive and inotropic agents administered during the first 24 hr of the ICU admission depicted 
as the inotropic score (short: p = 0.28, long: p = 0.048). Data presented as median and IQR. D, Renal function depicted as glomerular 
filtration rate (GFR) using plasma clearance of iohexol (GFRiohexol) and (E) estimated GFR with the Modification of Diet in Renal Disease 
equation (eGFRMDRD) (short: GFRiohexol: p = 0.47 and eGFRMDRD: p = 0.27, long: GFRiohexol: p = 0.02 and eGFRMDRD: p < 0.0001). Data are 
presented as mean and sem. p values calculated using Student t tests. *p < 0.05; #p < 0.1.
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The observed decrease in ICU and hospital length 
of stay in the EA-230 group compared with the pla-
cebo group may be explained by these beneficial cardi-
ovascular and putative renoprotective effects of EA-230. 
These results are in line with the lower overall occur-
rence of (S)AEs. EA-230 may exert its putative effect 
through direct action on organ function (e.g., kidney 
and vascular system), as no effect on the inflammatory 
response was evident. There are several limitations of 
this study. First, the single-dose design, which was based 
on previous work (38), excludes identification of a dose-
response effect. Nevertheless, our finding that the bene-
ficial effects of EA-230 are more pronounced in patients 
with longer duration of surgery, and thus infusion of 
study drug, suggest a dose-response effect. Therefore, 
one may argue that in future studies, longer infusion of 
EA-230 should be evaluated. Second, the generalizability 
might be limited, as the study population in this mono-
center study was restricted to patients in the Netherlands 
and predominantly consisted of males, although an over-
representation of males is typical in patients undergoing 
cardiac surgery. Third, the considerable number of end-
points may have increased the chances of type 1 errors. 
Therefore, the analyses of these endpoints should be con-
sidered exploratory and hypothesis-generating and must 
be interpreted with caution.
CONCLUSIONS
In summary, in cardiac surgery patients treated with 
EA-230, no safety issues emerged. EA-230 did not in-
fluence the postoperative inflammatory response. 
However, beneficial trends on renal and cardiovascular 
variables were observed. Furthermore, length of stay was 
shortened after EA-230 administration. Confirmation 
of these findings and their relationship with timing and 
duration of EA-230 infusion are warranted.
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